Want to see HK:9966 full AI Analyst Report?
Alphamab Oncology (9966) AI Stock Analysis
Top Page
Alphamab Oncology
(HKEX:9966)
The score is primarily held back by volatile financial performance—2025 revenue decline, losses, and negative operating/free cash flow—despite a relatively strong gross margin and low leverage. Technicals add further pressure with price below major moving averages and a negative MACD. Valuation is also challenged by losses (negative P/E) and no provided dividend yield.
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 6.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.24M
- Price to Earnings (P/E)
- -30.7
- Beta (1Y)
- 0.81
- Revenue Growth
- -31.77%
- EPS Growth
- -177.01%
- Country
- Hong Kong
- Employees
- 515
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Alphamab Oncology Business Overview & Revenue Model
Company Description
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key...
How the Company Makes Money
Alphamab Oncology primarily makes money through (1) commercialization of its approved oncology drugs (where approvals and commercial launches have occurred), generating revenue from product sales through its own sales efforts and/or commercial partne...
Alphamab Oncology Financial Statement Overview
Summary
Financials are mixed: strong gross margin (~77% in 2025) and a conservatively levered balance sheet (debt-to-equity ~0.07) are positives, but 2025 saw a sharp revenue decline (~30%), a return to net losses (~111M), and renewed cash burn (operating cash flow ~-122M; free cash flow ~-153M), increasing execution and funding-risk sensitivity.
Income Statement
47NeutralBalance Sheet
74PositiveCash Flow
39Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 514.22M | 551.58M | 640.08M | 218.77M | 166.84M | 146.02M |
| Gross Profit | 391.26M | 426.67M | 579.77M | 163.54M | 122.64M | 142.99M |
| EBITDA | -130.73M | -84.64M | 178.04M | -129.30M | -377.18M | -358.13M |
| Net Income | -173.76M | -110.99M | 166.34M | -210.59M | -325.72M | -412.42M |
Balance Sheet | ||||||
| Total Assets | 2.16B | 2.10B | 2.24B | 2.14B | 2.12B | 2.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.43B | 1.35B | 1.57B | 1.41B | 1.35B | 1.99B |
| Total Debt | 268.36M | 123.03M | 185.96M | 257.08M | 345.39M | 637.27M |
| Total Liabilities | 490.98M | 386.33M | 409.87M | 465.00M | 559.86M | 834.80M |
| Stockholders Equity | 1.67B | 1.71B | 1.83B | 1.67B | 1.56B | 1.87B |
Cash Flow | ||||||
| Free Cash Flow | -171.69M | -153.48M | 190.56M | -239.02M | -429.96M | -478.72M |
| Operating Cash Flow | -155.89M | -121.89M | 212.34M | -202.84M | -300.31M | -320.60M |
| Investing Cash Flow | -248.34M | -628.85M | -92.93M | -18.11M | 850.76M | 574.26M |
| Financing Cash Flow | -26.59M | -98.31M | -98.96M | 218.07M | -310.90M | 363.90M |
Alphamab Oncology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9966, the sentiment is Negative. The current price of 6.21 is below the 20-day moving average (MA) of 7.12, below the 50-day MA of 7.83, and below the 200-day MA of 8.47, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 34.92 is Neutral, neither overbought nor oversold. The STOCH value of 36.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9966.
Alphamab Oncology Peers Comparison
Overall Rating
HK:999566Neutral
HK:269664.6Neutral- HK:996647Neutral
HK:261646.6Neutral
HK:187741.25Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9995 | 66Neutral | HKD 51.82B | 7.89 | 105.60% | ― | 292.84% | ― |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9966 | 47Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:9995 | RemeGen Co. Ltd. Class H | 64.85 | -28.00 | -30.16% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Alphamab Oncology Corporate Events
Alphamab Oncology Launches HK$80 Million On-Market Share Buyback Plan
Alphamab Oncology has approved an on-market share repurchase program of up to HK$80 million, to be executed from time to time under an existing shareholder mandate valid until the next annual general meeting or its earlier expiry. The buyback will be...
Alphamab Oncology Swings to Loss as R&D Surge Drives Aggressive Cancer Pipeline Expansion
Alphamab Oncology reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB271.2 million, down from RMB319.4 million a year earlier, and a swing to a net loss of RMB40.5 million from a profit of RMB21.6 million...
Alphamab Oncology’s HER2 Drug Anbenitamab Wins Priority NMPA Review for First-Line Breast Cancer
Alphamab Oncology said China’s National Medical Products Administration has accepted, with priority review status, its new drug application for Anbenitamab (KN026) combined with CSPC Group’s albumin-bound docetaxel (HB1801) as a first-lin...
Alphamab Oncology Sets Board Meeting to Approve 2026 Interim Results
Alphamab Oncology has scheduled a board meeting for August 27, 2026, to review and approve its interim results for the six months ended June 30, 2026. The meeting will also address the publication of these results and any other business, signaling up...
Alphamab’s Anbenitamab Breast Cancer NDA Gains Priority Review in China
Alphamab Oncology has announced that China’s National Medical Products Administration has accepted, under priority review, its new drug application for the HER2 bispecific antibody Anbenitamab, used in combination with CSPC Group’s albumi...
Alphamab licenses key cancer drug JSKN016 to Pathos AI in US$2.1 billion-plus deal
Alphamab Oncology’s subsidiary Jiangsu Alphamab has licensed its in-house bispecific antibody-drug conjugate JSKN016 to U.S.-based Pathos AI for development and commercialization outside mainland China, Hong Kong, Macau and Taiwan. The deal gra...
Alphamab Wins China Phase III Nod for Novel Cervical Cancer Therapy
Alphamab Oncology has secured approval from China’s Center for Drug Evaluation to initiate a phase III clinical trial of JSKN033, a high-concentration subcutaneous co-formulation combining a HER2-targeting antibody-drug conjugate and a PD-L1 im...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026